Clinical trials: Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC).
- Trial name
- NCT03394781
- Testing
- DUR-928
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Durect
Primary Sclerosing Cholangitis (PSC)
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
- Trial name
- NCT01672853
- Testing
- Simtuzumab
- Where
- 75 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- Gilead Sciences
Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis
NKT Role in the Regulation of the Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). These diseases are a public health problem because they concern many patients (1 case in 1000).
- Trial name
- NKT-CSP/MICI (NCT02884557)
- Testing
- collection of gut biopsies collection of blood samples
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Lille
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Primary Sclerosing Cholangitis, Colitis
Evaluation of DHA for the Treatment of PSC
The researches aim to study the effects of DHA (component of fish oil) on patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that DHA might reverse the problems associated with PSC.
- Trial name
- NCT00325013
- Testing
- Docosahexaenoic Acid (DHA)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cholangitis, Sclerosing, Liver Cirrhosis, Biliary
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
OBJECTIVES: I. Assess the safety and effectiveness of budesonide in patients with primary sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to ursodeoxycholic acid. II.
- Trial name
- NCT00004842
- Testing
- budesonide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Sclerosing Cholangitis
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
This is a randomized, double-blind, placebo controlled multicenter study. A total of 700 patients will be included. After an updated powercalculation 560 was condidered enough The study will include patients with primary…
- Trial name
- PiSCATIN (NCT04133792)
- Testing
- Simvastatin 40mg
- Where
- 12 sites in Sweden
- Volunteers
- 571 people
- Sponsor
- Annika Bergquist
Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis
A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). Although rare, PSC is associated with significant and disproportionate unmet needs; with heightened risks of…
- Trial name
- PSC-Vanc (NCT05376228)
- Testing
- Oral Vancomycin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Primary Sclerosing Cholangitis
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
This is an open-label, active treatment trial to determine the pharmacokinetics of orally administered ursolic acid and to assess the potential efficacy and safety of ursolic acid in subjects with primary sclerosing cholangitis…
- Trial name
- NCT03216876
- Testing
- Ursolic acid
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Davis
Cholangitis, Sclerosing
Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis
The purpose of this research study is to determine whether the combination of UDCA and ATRA taken for 3 months will improve laboratory tests of liver and bile duct inflammation in patients with Primary Sclerosing Cholangitis…
- Trial name
- NCT01456468
- Testing
- Oral all-trans retinoic acid (ATRA)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Yale University
Primary Sclerosing Cholangitis, Biliary Atresia
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism.
- Trial name
- NCT02137668
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sacramento Pediatric Gastroenterology
Primary Sclerosing Cholangitis
Minocycline in Primary Sclerosing Cholangitis (PSC)
The purpose of the study is to see how safe and effective minocycline is in the treatment of Primary Sclerosing Cholangitis (PSC).
- Trial name
- NCT00630942
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Primary Sclerosing Cholangitis
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
- Trial name
- NCT02704364
- Testing
- NGM282
- Where
- 38 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Primary Sclerosing Cholangitis (PSC)
S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)
The aim of this study is to investigate clinical effects (liver biochemistries, health-related quality of life, liver stiffness) and underlying mechanisms of hepatoprotection of S-adenosylmethionine in patients with primary…
- Trial name
- NCT06026865
- Testing
- S-Adenosyl-L-methionine (SAMe)
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Warsaw
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) in non-end-stage primary sclerosing cholangitis (PSC) participants with underlying inflammatory bowel disease (IBD).
- Trial name
- NCT03035058
- Testing
- Vedolizumab
- Sponsor
- Takeda
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis
The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis.
- Conditions
- Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), Pediatric Inflammatory Bowel Diseases
- Trial name
- VERDA (NCT07646223)
- Testing
- Oral Vancomycin
- Where
- Finland
- Volunteers
- 140 people
- Sponsor
- Tampere University Hospital
Primary Sclerosing Cholangitis
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
Patients with primary sclerosing cholangitis (PSC) are affected by an inflammatory condition of the bile ducts. Unfortunately, patients with PSC have a 10 to 15 percent lifetime risk of developing gallbladder and bile duct…
- Trial name
- NCT00951327
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Short Bowel Syndrome, Intestinal Resection
Gastrointestinal Hormone Secretion, Intestinal Permeability and Short Bowel Syndrome
The gastrointestinal tract is a complex endocrine organ that regulates a wide range of physiological processes, including those involved in the digestion of nutrients.
- Trial name
- NCT07235670
- Testing
- Standardized meal
- Where
- Denmark
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary Sclerosing Cholangitis
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
The objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (PSC), as well as the key impacts of symptoms on patients' day-to-day functioning.
- Trial name
- NCT02247934
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
- Trial name
- NCT02808312
- Testing
- Cilofexor
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences